Adaptimmune Therapeutics plc (NASDAQ:ADAP) price is hovering lower on Monday, September 13, dropping -5.98% below its previous close.
A look at today’s price movement shows that the recent level at last check reads $5.85, with intraday deals fluctuating between $5.75 and $6.84. The company’s 5Y monthly beta was ticking 2.16. Taking into account the 52-week price action we note that the stock hit a 52-week high of $10.93 and 52-week low of $3.37. The stock added 52.74% on its value in the past month.
Adaptimmune Therapeutics plc, which has a market valuation of $903.59 million, is expected to release its quarterly earnings report Nov 03, 2021 – Nov 08, 2021. Analysts tracking ADAP have forecast the quarterly EPS to shrink by -0.26 per share this quarter, while the same analysts predict the annual EPS to hit -$0.98 for the year 2021 and up to -$1 for 2022. In this case, analysts estimate an annual EPS growth of -8.90% for the year and -2.00% for the next year.
The average estimate suggests sales growth for the quarter will likely rise by 14.80% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $5.21 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow 31.60% above that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 1 upward and no downward reviews. On the technical perspective front, indicators give ADAP a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 8 analysts have assigned ADAP a recommendation rating as follows: 4 rate it as a Hold; 3 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Adaptimmune Therapeutics plc (ADAP) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Hold, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that ADAP’s price is at present 10.65% off the SMA20 and 29.79% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 59.32, with weekly volatility standing at 14.39%. The indicator jumps to 9.05% when calculated based on the past 30 days. Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s beta value is holding at 2.13, while the average true range (ATR) indicator is currently reading 0.50. Considering analysts have assigned the stock a price target range of $4.00-$17.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $9.67. Based on this estimate, we see that today’s price at last check is roughly 27.27% off the estimated low and -209.09% off the forecast high. Investors will no doubt be excited to see the share price fall to $8.00, which is the median consensus price, and at that level ADAP would be -45.45% from recent price.
Turning out attention to how the Adaptimmune Therapeutics plc stock has performed in comparison to its peers in the industry, here’s what we find: ADAP’s stock is -5.98% on the day and -26.32% in the past 12 months, while Sangamo Therapeutics Inc. (SGMO) traded -0.84% in the latest session and is positioned -5.70% down on its price 12 months ago. Another comparison is with uniQure N.V. (QURE) whose stock price is up 2.47% in the current trading session, and has flourished -11.28% over the past year. Also, Enzo Biochem Inc. (ENZ) is currently showing down trend of -0.85% while its price kept floating at 62.10% over the past year. Elsewhere in the market, the S&P 500 Index has stumbled -0.14% in today’s early trading, with the Dow Jones Industrial also seeing a negative session so far with -0.46%.
An analysis of the Adaptimmune Therapeutics plc (NASDAQ:ADAP) stock in terms of its daily trading volume indicates that the 3-month average is 1.81 million.
Current records show that the company has 155.71M in outstanding shares. The insiders’ percentage holdings are 0.10% of outstanding shares while the percentage share held by institutions stands at 79.30%. But the 8.53% upside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.